{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:43:13Z","timestamp":1787161393577,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>\n                      Predicting which lung transplant recipients (LTR) will develop cytomegalovirus (CMV) infection remains challenging. The aim of this retrospective cohort study was to further explore the predictive utility of global immune biomarkers within recipient seropositive (R\n                      <jats:sup>+<\/jats:sup>\n                      ) LTRs, focusing on the mitogen component of the QuantiFERON (QF)-CMV assay and the absolute lymphocyte count (ALC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      R\n                      <jats:sup>+<\/jats:sup>\n                      LTR with QF-CMV testing performed at 5 mo posttransplant were included. ALC and mitogen were evaluated as predictors of CMV infection (&gt;150 IU\/mL) in plasma and\/or bronchoalveolar lavage fluid using Cox regression, controlling for antiviral prophylaxis. Optimal cutoffs were calculated with receiver-operating characteristic curves.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      CMV infection occurred in 111 of 204 patients (54%) and was associated with donor seropositivity (80\/111 [72%] versus 42\/93 [45%],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), lower ALC (median 1.1 versus 1.4\u2009\u00d7\u20091000 cells\/\u03bcL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.004), and lower mitogen (2.8 versus 4.6,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.03) values. Adjusted for serostatus and prophylaxis, each unit decrease in ALC (hazard ratio, 1.56 per 1000 cells\/\u03bcL; 95% confidence interval, 1.19-2.08;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.002) and mitogen (hazard ratio, 1.09 per 1 IU\/mL; 95% confidence interval, 1.03-1.14;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.001) were independently associated with CMV. Combining these 2 biomarkers did not substantially improve model performance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>\n                      In R\n                      <jats:sup>+<\/jats:sup>\n                      LTRs, donor serostatus, ALC values, and the mitogen component of the QF-CMV assay were able to predict postprophylaxis CMV infection. Combining serostatus with either biomarker alone improved predictions, but using both tests together did not increase predictive utility further. These values could be used to risk stratify patients and inform decision-making regarding the duration of antiviral prophylaxis and frequency of virologic monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005422","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:00:24Z","timestamp":1747994424000},"page":"1656-1664","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Global Immune Biomarkers and Donor Serostatus Can Predict Cytomegalovirus Infection Within Seropositive Lung Transplant Recipients"],"prefix":"10.1097","volume":"109","author":[{"given":"Bradley J.","family":"Gardiner","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Alfred Health, Melbourne, VIC, Australia."},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Alfred Health, Melbourne, VIC, Australia."},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allisa N.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Alfred Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory I.","family":"Snell","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, Monash University, Melbourne, VIC, Australia."},{"name":"Lung Transplant Service, Alfred Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen P.","family":"Westall","sequence":"additional","affiliation":[{"name":"School of Translational Medicine, Monash University, Melbourne, VIC, Australia."},{"name":"Lung Transplant Service, Alfred Health, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Alfred Health, Melbourne, VIC, Australia."},{"name":"School of Translational Medicine, Monash University, Melbourne, VIC, Australia."},{"name":"Infection Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia."},{"name":"Centre to Impact AMR, Monash University, Melbourne, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"R1-20250924","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome.","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"R2-20250924","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.healun.2020.10.009","article-title":"Risk factors for mortality in lung transplant recipients aged >\/=65 years: a retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients.","volume":"40","author":"Mosher","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"R3-20250924","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-20250924","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/528689","article-title":"Ganciclovir\/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.","volume":"46","author":"Chmiel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R5-20250924","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1164\/rccm.200310-1405OC","article-title":"Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.","volume":"170","author":"Tamm","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-20250924","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-5223(97)70144-2","article-title":"Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.","volume":"114","author":"Kroshus","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R7-20250924","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/ajrccm\/146.6.1419","article-title":"Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients.","volume":"146","author":"Duncan","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"R8-20250924","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R9-20250924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2012.04.036","article-title":"Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+\/R\u2013 kidney transplant patients receiving thymoglobulin induction.","volume":"45","author":"Luan","year":"2013","journal-title":"Transplant Proc"},{"key":"R10-20250924","doi-asserted-by":"crossref","first-page":"240","DOI":"10.15171\/jnp.2017.39","article-title":"Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study.","volume":"6","author":"Navarro-Rodriguez","year":"2017","journal-title":"J Nephropathol"},{"key":"R11-20250924","doi-asserted-by":"crossref","first-page":"e12929","DOI":"10.1111\/tid.12929","article-title":"Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease.","volume":"20","author":"Reusing","year":"2018","journal-title":"Transplant Infect Dis"},{"key":"R12-20250924","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation.","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"R13-20250924","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R14-20250924","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation.","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"R15-20250924","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2022.05.004","article-title":"Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.","volume":"41","author":"Gardiner","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R16-20250924","doi-asserted-by":"crossref","first-page":"e1501","DOI":"10.1097\/TXD.0000000000001501","article-title":"Cytomegalovirus immunity assays predict viremia but not replication within the lung allograft.","volume":"9","author":"Li","year":"2023","journal-title":"Transplant Direct"},{"key":"R17-20250924","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.trre.2018.10.001","article-title":"Can immune biomarkers predict infections in solid organ transplant recipients? A review of current evidence.","volume":"33","author":"Dendle","year":"2019","journal-title":"Transplant Rev (Orlando)"},{"key":"R18-20250924","doi-asserted-by":"crossref","first-page":"e14020","DOI":"10.1111\/tid.14020","article-title":"Pathogen-agnostic immune biomarkers that predict infection after solid organ transplantation.","volume":"25","author":"Imlay","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"R19-20250924","doi-asserted-by":"crossref","first-page":"104871","DOI":"10.1016\/j.jcv.2021.104871","article-title":"Torque teno virus loads after kidney transplantation predict allograft rejection but not viral infection.","volume":"140","author":"van Rijn","year":"2021","journal-title":"J Clin Virol"},{"key":"R20-20250924","doi-asserted-by":"crossref","first-page":"e13489","DOI":"10.1111\/tid.13489","article-title":"Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: is there a \u201csafe corridor\u201d after kidney transplantation?","volume":"23","author":"El Helou","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R21-20250924","doi-asserted-by":"crossref","first-page":"e13550","DOI":"10.1111\/tid.13550","article-title":"Evaluation of Quantiferon(R)-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients.","volume":"23","author":"Gardiner","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R22-20250924","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients.","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R23-20250924","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/TP.0000000000002396","article-title":"Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients.","volume":"103","author":"Meesing","year":"2019","journal-title":"Transplantation"},{"key":"R24-20250924","doi-asserted-by":"crossref","first-page":"e3797","DOI":"10.1093\/cid\/ciaa1800","article-title":"Association between lymphopenia at 1 month posttransplant and infectious outcomes or death in heart transplant recipients.","volume":"73","author":"Perry","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R25-20250924","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/tri.12816","article-title":"Monitoring of intracellular adenosine triphosphate in CD4(+) T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients.","volume":"29","author":"Perez-Jacoiste Asin","year":"2016","journal-title":"Transpl Int"},{"key":"R26-20250924","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.transproceed.2016.01.046","article-title":"Clinical utility of QuantiFERON-Cytomegalovirus test in management of kidney transplant recipients.","volume":"48","author":"Tarasewicz","year":"2016","journal-title":"Transplant Proc"},{"key":"R27-20250924","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R30-20250924","doi-asserted-by":"crossref","first-page":"e13094","DOI":"10.1111\/tid.13094","article-title":"High incidence of clinically significant cytomegalovirus infection in CMV D+\/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.","volume":"21","author":"Kabbani","year":"2019","journal-title":"Transplant Infect Dis"},{"key":"R31-20250924","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-6143.2012.04339.x","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?","volume":"13","author":"Schoeppler","year":"2013","journal-title":"Am J Transplant"},{"key":"R32-20250924","doi-asserted-by":"crossref","first-page":"veac076","DOI":"10.1093\/ve\/veac076","article-title":"Human cytomegalovirus strain diversity and dynamics reveal the donor lung as a major contributor after transplantation.","volume":"8","author":"Kulekci","year":"2022","journal-title":"Virus Evol"},{"key":"R33-20250924","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1086\/598952","article-title":"An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.","volume":"199","author":"Manuel","year":"2009","journal-title":"J Infect Dis"},{"key":"R34-20250924","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/518571","article-title":"Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes.","volume":"45","author":"Ishibashi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R35-20250924","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1681\/ASN.2013040340","article-title":"Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.","volume":"24","author":"Shabir","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R36-20250924","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00408-020-00380-z","article-title":"Risk factors for cytomegalovirus reactivation in lung transplant recipients.","volume":"198","author":"Kwak","year":"2020","journal-title":"Lung"},{"key":"R37-20250924","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/TP.0000000000004360","article-title":"Absolute lymphocyte count as a marker for cytomegalovirus infection after heart transplantation.","volume":"107","author":"Schoeberl","year":"2023","journal-title":"Transplantation"},{"key":"R38-20250924","doi-asserted-by":"crossref","first-page":"1180769","DOI":"10.3389\/fmed.2023.1180769","article-title":"Torque teno virus viremia and QuantiFERON\u00ae-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients.","volume":"10","author":"Mafi","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R39-20250924","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.pathol.2018.04.002","article-title":"Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.","volume":"50","author":"Thompson","year":"2018","journal-title":"Pathology"},{"key":"R40-20250924","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis.","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:01:21Z","timestamp":1758744081000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005422","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}